Karyopharm Therapeutics Inc - Asset Resilience Ratio

Latest as of December 2025: 2.96%

Karyopharm Therapeutics Inc (KPTI) has an Asset Resilience Ratio of 2.96% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Karyopharm Therapeutics Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$3.20 Million

Cash + Short-term Investments

Total Assets

$108.42 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Karyopharm Therapeutics Inc's Asset Resilience Ratio has changed over time. See Karyopharm Therapeutics Inc (KPTI) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Karyopharm Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Karyopharm Therapeutics Inc (KPTI) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$3.20 Million	2.96%
Total Liquid Assets	$3.20 Million	2.96%

Asset Resilience Insights

Limited Liquidity: Karyopharm Therapeutics Inc maintains only 2.96% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Karyopharm Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Karyopharm Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Karyopharm Therapeutics Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Karyopharm Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.96%	$3.20 Million	$108.42 Million	-25.17pp
2024-12-31	28.12%	$46.24 Million	$164.42 Million	-29.78pp
2023-12-31	57.90%	$139.21 Million	$240.44 Million	+18.04pp
2022-12-31	39.86%	$142.78 Million	$358.17 Million	+27.37pp
2021-12-31	12.50%	$38.16 Million	$305.31 Million	-39.67pp
2020-12-31	52.17%	$163.32 Million	$313.05 Million	+7.05pp
2019-12-31	45.12%	$133.10 Million	$294.96 Million	-16.48pp
2018-12-31	61.60%	$210.18 Million	$341.19 Million	+18.63pp
2017-12-31	42.97%	$77.47 Million	$180.29 Million	-1.32pp
2016-12-31	44.29%	$79.89 Million	$180.38 Million	-10.15pp
2015-12-31	54.43%	$117.28 Million	$215.44 Million	+29.42pp
2014-12-31	25.01%	$55.12 Million	$220.34 Million	--
2013-12-31	0.00%	$0.00	$158.23 Million	--

pp = percentage points

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology

Market Cap

$211.98 Million

Market Cap Rank

#16668 Global

#3893 in USA

Share Price

$9.40

Change (1 day)

+3.30%

52-Week Range

$3.77 - $10.09

All Time High

$27.72